Mbiomics focuses on developing the first generation of effective live bacterial therapeutics. The company uses its proprietary profiling platform and computational technologies to generate high-resolution precision data for microbiota modulation. The technology is intended to enable a better understanding of the interactions between the gut microbiome and the host, allowing Mbiomics to develop microbial consortia that can be delivered to patients as precision therapies. The Munich-based company BiotechThe company aims to revolutionize the treatment of a wide range of diseases, from cancer to inflammatory bowel diseases.
“Harnessing the power of the microbiome to treat diseases”
Markus Rinecker, Co-founder and CMO of Mbiomics, says:
"The microbiome offers a rich source of new therapeutic opportunities that have not yet been fully explored. Our goal is to harness the power of the microbiome to treat diseases that are difficult to treat with conventional approaches. Our outstanding R&D team has delivered a technological proof of concept for our analysis platform in record time. With this technology, Mbiomics is uniquely positioned to understand microbiome modulation and develop effective therapies."
Laura Figulla, Co-founder and CEO of Mbiomics, adds:
"We are delighted to have the support of such a distinguished group of investors who share our vision of harnessing the power of the gut microbiome to develop targeted therapies. This financing allows us to build our platform, accelerate the selection of our first lead product candidates, and intensify research activities toward clinical validation."
“Great potential”
“The influence of the microbiome on diseases is currently being widely researched,”
so Monika Steger, Managing Director of Bayern Kapital.
"Mbiomics shows great potential in the development of microbiome-based therapeutics for supportive intervention in various diseases and can thus advance research a decisive step forward. We look forward to pursuing this path together with the company and an experienced and financially strong investor consortium."
And Jan Engels, Investment Manager at High-Tech Gründerfonds, adds:
"In the development of live bacterial products, microbiome profiling remains one of the most challenging aspects. Mbiomics has developed a novel high-performance profiling platform that addresses the key bottlenecks in the development of microbiome-based therapeutic approaches using novel bacterial consortia. We are pleased to invest in an excellent team and innovative technology together with strong co-investors,"
